Rhumbline Advisers Makes New Investment in CeriBell (NASDAQ:CBLL)

Rhumbline Advisers bought a new position in shares of CeriBell (NASDAQ:CBLL) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 12,353 shares of the company’s stock, valued at approximately $320,000.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CBLL. Canaccord Genuity Group reiterated a “buy” rating and issued a $33.00 price objective on shares of CeriBell in a research note on Wednesday, February 26th. TD Cowen boosted their price target on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $32.60.

CeriBell Stock Up 2.1 %

Shares of CBLL opened at $22.69 on Monday. CeriBell has a 12-month low of $18.69 and a 12-month high of $32.75. The business’s 50-day simple moving average is $22.93.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million during the quarter, compared to analysts’ expectations of $17.55 million. As a group, research analysts anticipate that CeriBell will post -2.46 earnings per share for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.